Clinical Trial

NeuroOne® CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today’s Marketplace

EDEN PRAIRIE, Minn., March 18, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a…

9 months ago

Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain

-- Company taps first EU distributors, Comercial Medico Quirurigca, SA and Durgalab, as the first globally to be granted rights…

9 months ago

Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain

Opioid-free and addiction-free pain treatment therapy could address $1.5B worldwide CINP marketATLANTA, March 18, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics,…

9 months ago

Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025

WAYNE, Pa., March 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and…

9 months ago

March 2025 Letter to Shareholders

VANCOUVER, Washington, March 18, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As envisioned, 2025 is unfolding to be an exciting year…

9 months ago

Clario announces acquisition of imaging provider NeuroRx

Acquisition further builds on Clario's neuroscience expertise and capabilities PHILADELPHIA, March 17, 2025 /PRNewswire/ -- Clario, a leading provider of…

9 months ago

Springbok Analytics Leads MRI Innovations in Multi-Site Pediatric FSHD Clinical Study

AI-Driven Muscle Analysis to Support MOVE Peds Study, Advancing Trial Readiness for Pediatric FSHD CHARLOTTESVILLE, Va., March 17, 2025 /PRNewswire/…

9 months ago

IgniteData launches cutting edge data integration platform for clinical trials at Cambridge University Hospitals

CAMBRIDGE, United Kingdom, March 17, 2025 /PRNewswire/ -- IgniteData has announced a collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) and Cambridge University Hospitals…

9 months ago

Hemostemix’s Pitch to Wall Street: ACP-01 Vascular Dementia Trial will Generate $5,365,000, Capture Data, as a Phase 1 Clinical Trial

Calgary, Alberta--(Newsfile Corp. - March 17, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an…

9 months ago

PEP-Therapy receives FDA Orphan Drug Designation for PEP-010 for treatment of Pancreatic Cancer

Press release PEP-Therapy receives FDA Orphan Drug Designation for PEP-010for treatment of Pancreatic Cancer Paris (France), March 17, 2025 –…

9 months ago